Answers are grounded in this paper and cite their sources.
Glycolytic metabolism in cancer is regulated by nonmalignant components of the tumor microenvironment, such as tumor-associated macrophages (TAMs). This study aimed to clarify the role of fatty acid–binding protein 4 + (FABP4 + ) TAMs in promoting lung cancer progression by reprogramming glycolytic metabolism. Immunohistochemistry, immunofluorescence, and positron emission tomography and computed tomography imaging were used to quantify the abundance of FABP4 + TAMs in a cohort of 283 patients with lung cancer. Functional assays and molecular analyses demonstrated that FABP4 + TAMs promoted tumor cell glycolysis by activating the tumor necrosis factor-α (TNF-α)–MYC axis, a mechanism independently validated in immunocompromised mice bearing subcutaneous lung cancer xenografts. Tumors with high infiltration of FABP4 + TAMs exhibited significant enrichment of glycolysis-related gene signatures. Furthermore, the overall glycolytic burden in tumor lesions was positively correlated with the infiltration abundance of FABP4 + TAMs. Mechanistically, FABP4 + TAMs secreted TNF-α, which upregulated MYC expression in lung cancer cells, leading to transcriptional upregulation of glucose transporter type 1, increased glucose uptake, and enhanced glycolytic flux. These effects were consistently observed in vitro and validated in subcutaneous lung cancer xenograft models. Overall, this study demonstrated that FABP4 + TAMs enhanced glycolysis in lung cancer cells through the TNF-α–MYC signaling pathway. Our findings indicate that pharmacologic or genetic targeting of FABP4 + TAMs can exert antitumor effects by disrupting their support of tumor glycolysis in preclinical models, suggesting a mechanistically grounded therapeutic strategy for lung cancer.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: